Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-fwgfc Total loading time: 0 Render date: 2024-07-10T14:37:38.595Z Has data issue: false hasContentIssue false

35 - Perioperative management of patients with Parkinson's disease

Published online by Cambridge University Press:  12 January 2010

By
Jorge L. Juncos
Edited by
Michael F. Lubin ,
Robert B. Smith ,
Thomas F. Dodson ,
Nathan O. Spell  and
H. Kenneth Walker
Jorge L. Juncos
Affiliation:
Emory University, School of Medicine, Atlanta, GA
Michael F. Lubin
Affiliation:
Emory University, Atlanta
Robert B. Smith
Affiliation:
Emory University, Atlanta
Thomas F. Dodson
Affiliation:
Emory University, Atlanta
Nathan O. Spell
Affiliation:
Emory University, Atlanta
H. Kenneth Walker
Affiliation:
Emory University, Atlanta
Get access

Summary

Introduction and overview of Parkinson's disease

Patients with Parkinson's disease (PD) face surgery more often than their age-matched counterparts due to injuries provoked by the gait and balance difficulties that characterize the advanced stages of this illness. Recent advances in neurosurgical techniques and an improved understanding of the pathophysiology of motor symptoms in PD has led to a renewed interest and an increase in the number of patients under going various neurosurgical procedures for PD. This chapter provides an overview of the principles and preoperative management of patients with Parkinson's disease (PD) and other parkinsonian states.

Parkinson's disease is an adult-onset neurodegenerative disorder characterized by progressive slowness of movement (bradykinesia), muscular rigidity, tremor, short stepped and stooped gait, and varying degrees of cognitive impairment. It affects close to 1 million mostly elderly Americans with an annual incidence of 20 new cases per 100 000 and a prevalence of 130 cases per 100 000. Its primary pathology is limited to the brain and consists of selective degeneration of the nigrostriatal dopaminergic pathway and the presence of Lewy bodies and Lewy neurites in surviving mesencephalic dopamine neurons, as well as in other brainstem and cortical neurons. Biochemically, the denervation results in striatal dopamine depletion which is linked to the above signs and symptoms. The cause of selective neuronal death, and therefore the etiology of PD is unknown, although hereditary and environmental factors are thought to play a role.

Type
Chapter
Information
Medical Management of the Surgical Patient
A Textbook of Perioperative Medicine
 , pp. 430 - 438
Publisher: Cambridge University Press
Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z.et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. 1993; 329: 162–167.CrossRefGoogle ScholarPubMed
Barr, A. The Shy–Drager syndrome. In Vinken, P. J., Bruyn, G. W., & Klawans, H. L., eds. Handbook of Clinical Neurology (vol 38). New York: Elsevier-North Holland, 1979: 233–256.Google Scholar
Berry, P. & Ward-Smith, P. A.Adrenal medullary transplant as a treatment for Parkinson's disease: perioperative considerations. J. Neurosci. Nurs. 1988; 20: 356–361.CrossRefGoogle ScholarPubMed
Brindle, G. F.Anesthesia in the patient with Parkinsonism. Primary Care 1977; 4: 513–528.Google ScholarPubMed
Brod, T. M.Fluoxetine and extrapyramidal side effects. Am. J. Psychiatry 1989; 146: 399–400.CrossRefGoogle Scholar
Broussolle, E., Marion, M. H., & Pollack, P.Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery. Lancet 1992; 340: 860.CrossRefGoogle ScholarPubMed
Cohen, G.The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J. Neural Transm. 1983; 19: 89–103.Google ScholarPubMed
Cummings, J. L.Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J. Geriatr Psychiatry Neurol. 1988; 1: 24–36.Google ScholarPubMed
Delgado, J. M. & Billo, J. M.Care of the patient with Parkinson's disease: surgical and nursing interventions. J. Neurosci. Nurs. 1988; 20: 142–150.CrossRefGoogle ScholarPubMed
Folstein, M. F., Folstein, S. E., & McHugh, P. R.“Mini-mental state.” A practical method for grading the state of patients for the clinician. J. Psychiatry Res. 1975; 12: 189–198.CrossRefGoogle ScholarPubMed
Forno, L. S. Pathology of Parkinson's disease. In Marsden, C. E. & Fahn, S., eds. Movement Disorders. London: Butterworths, 1982: 25–40.Google Scholar
Frankel, J. P., Lees, A. J., Kempster, P. A., & Stern, G. M.Subcutaneous apomorphine in the treatment of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1990; 53: 96–101.CrossRefGoogle ScholarPubMed
Golden, W. E., Lavender, R. C., & Metzer, W. S.Acute postoperative confusion and hallucinations in Parkinson disease. Ann. Int. Med. 1989; 111: 218–222.CrossRefGoogle ScholarPubMed
Guze, B. H. & Baxter, L. R.Neuroleptic malignant syndrome. N. Engl. J. Med. 1985; 313: 163–166.CrossRefGoogle ScholarPubMed
Hornykiewicz, O. and Kish, S. J.Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 1987; 45: 19–34.Google ScholarPubMed
Hyman, S. A., Rogers, W. D., Smith, D. W.et al. Perioperative management for transplant of autologous adrenal medulla to the brain for Parkinsonism. Anesthesiol. 1988; 69: 618–622.CrossRefGoogle ScholarPubMed
Irwin, R. P., Nutt, J. G., Woodward, W. R.et al. Pharmacodynamics of the hypotensive effect of levodopa in Parkinsonian patients. Clin. Neuropharmacol. 1992; 15: 365–374.CrossRefGoogle ScholarPubMed
Jansen Steur, E. N. H.Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43: 211–213.CrossRefGoogle Scholar
Jenner, P., Dexter, D. T., Sian, J.et al. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. 1992; 32(suppl): 82–87.CrossRefGoogle ScholarPubMed
Juncos, J. L.Levodopa: pharmacology, pharmacokinetics and pharmacodynamics. Neurol. Clin. N. Amer. 1992; 487–509.CrossRefGoogle ScholarPubMed
Juncos, J. L. Diet and related variables in the management of Parkinson disease. In Schneider, J. S. & Gupta, M., eds. Current Concepts in Parkinson's Disease. Toronto: Hogrefe & Huber, 1993: 365–402.Google Scholar
Kaufman, C. A. & Wyatt, R. J. Neuroleptic malignant syndrome. In Meltzer, H., ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987.Google Scholar
Kurlan, R., Nutt, J. G., Woodward, W. R.et al. Duodenal and gastric delivery of levodopa in parkinsonism. Ann. Neurol. 1988; 22: 589–595.CrossRefGoogle Scholar
Lipowski, Z. J.Delirium in the elderly patient. N. Engl. J. Med. 1989; 320: 578–582.Google ScholarPubMed
Mayeux, R., Stern, Y., Rosenstein, R.et al. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch. Neurol. 45: 260–262.CrossRef
Mayeux, R., Stern, Y., Rosen, , et al. Depression, intellectual impairment and Parkinson's disease. Neurology 1981; 31: 645–650.CrossRefGoogle Scholar
Merli, G. J. & Bell, R. D.Preoperative management of the surgical patient with neurologic disease. Med. Clin. N. Amer. 1987; 71: 511–527.CrossRefGoogle ScholarPubMed
Mier, M.Mechanisms leading to hypoventilation in extrapyramidal disorders, with special reference to Parkinson's disease. J. Am. Geriatr. Soc. 1976; 15: 230–238.CrossRefGoogle Scholar
Mitchelson, F.Pharmacological agents affecting emesis. A review (Part 1). Drugs 1992; 43: 295–315.CrossRefGoogle Scholar
Nobrega, F. T., Glattre, E., Kurland, L. T., & Okazaki, H. Comments on the epidemiology of parkinsonism including prevalence and incidence statistics for Rochester, Minnesota, 1935–1966. In Barbeau, A. & Brunette, J. R., eds. Progress in Neurogenetics. Amsterdam: Excerpta Medica, 1969.Google Scholar
Paulson, G. & Tafrate, R.Some “minor” aspects of Parkinsonism, especially pulmonary function. Neurology 1970; 20: 14–17.CrossRefGoogle ScholarPubMed
Pfeiffer, R. F., Kang, J., Graber, B.et al. Clozapine for psychosis in Parkinson's disease. Movement Dis. 1990; 5: 239–242.CrossRefGoogle ScholarPubMed
Rajput, A. H., Offord, K. P., Beard, C. M., & Kurland, L. T.Epidemiology of parkinsonism: incidence, classification, and mortality. Ann. Neurol. 1984; 16: 278–282.CrossRefGoogle Scholar
Reed, A. P. & Han, D. G.Intraoperative exacerbation of Parkinson's disease. Anesth. Analg. 1992; 75: 850–853.CrossRefGoogle ScholarPubMed
Ropper, A. H., ed. Neurological and Neurosurgical Intensive Care. New York, NY: Raven Press, 1993.Google Scholar
Sage, J. I., Schuh, L., Heikkila, R. E., & Duvoisin, R. C.Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease. Clin. Neuropharmacol. 1988; 11: 36–44.CrossRefGoogle ScholarPubMed
Scuderi, P., Wetchler, B., Sung, Y.-F.et al. Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. Anesthesiology 1993; 78: 15–20.CrossRefGoogle ScholarPubMed
Steele, J. C.Progressive supranuclear palsy. Brain 1972; 95: 693–704.Google ScholarPubMed
Suchowersky, O. & deVries, J.Possible interactions between deprenyl and fluoxetine. Canad. J. Neurol. Sci. 1990; 17: 352–353.CrossRefGoogle Scholar
Tanner, C. M.Epidemiology of Parkinson's disease. Neurol. Clin. N. Amer. 1992; 10: 317–327.CrossRefGoogle ScholarPubMed
Vincken, W. G., Bauthier, S. G., Dohlfuss, R.et al. Involvement of upper airway muscles in extrapyramidal disorders. A cause for airflow limitation. N. Engl. J. Med. 1984; 311: 438–442.CrossRefGoogle ScholarPubMed
Zoldan, J., Friedberg, G., Goldberg-Stern, H., & Melamed, E.Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993; 341: 562–563.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×